An interventional study of eCoin Tibial Nerve Stimulation in Overactive Bladder, Urge Incontinence and Incontinence, Urinary, sponsored by Valencia Technologies Corporation. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-17.
Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 213th largest by enrollment of the 288 interventional ones that give a count, is one of 19 that started in 2019, is one of 113 with no phase, and was the 205th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 21+ · Women only
Vensica Therapeutics Ltd. · Sites in United States
Ages 18–80 · Women only
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
333 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 35 · Phase 3 52 · Phase 4 71
First in 2002; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 70 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 66 across the 288 interventional studies, 91 across the 43 observational. Of the 259 that completed or were terminated, 134 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 333 have an industry lead sponsor. The 10 most frequent:
Valencia Technologies Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Valencia Technologies Corporation has 3 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
20 of the studies in Urinary Bladder, Overactive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07405554Endeavor HealthZinc Supplementation With Botulinum Toxin for Overactive Bladder | 2026-12 |
| NCT05200923MedtronicNeuroPelvic Health Electrically Evoked Recording (PEER) 2 Study | 2026-12-18 |
Add all 20 to your calendar (.ics) → With an account.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American Urological Association (30). The follow-on study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient-reported outcomes through 24 weeks of eCoinTM therapy (which is the same as 28 weeks from study device reimplantation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: eCoin Tibial Nerve Stimulation
Subcutaneous stimulation of the tibial nerve using the eCoin device.
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Time frame: 12 weeks after device activation.
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation.
Instances of a related adverse event.
Time frame: 16 weeks after device implantation.
Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Time frame: 24 weeks after device activation.
Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation.
Instances of a related adverse event
Time frame: 28 weeks after device implantation.
| Milestone | eCoin Tibial Nerve Stimulation |
|---|---|
| Started | 23 |
| Completed | 22 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
| episodes/day | eCoin Tibial Nerve Stimulation |
|---|---|
| Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | -2.2 ± 3.3 |
Instances of a related adverse event.
| adverse events | eCoin Tibial Nerve Stimulation |
|---|---|
| Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 4 Months After Implantation. | 8 |
| episodes/day | eCoin Tibial Nerve Stimulation |
|---|---|
| Change From Baseline in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. | -3.7 ± 1.2 |
Instances of a related adverse event
| adverse events | eCoin Tibial Nerve Stimulation |
|---|---|
| Safety in All Patients. All Adverse Events Will be Reported in All Patients Who Were Implanted 6 Months After Implantation. | 8 |
Collected over 28 weeks after implantation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| eCoin Tibial Nerve Stimulation | 0/23 (0%) | 0/23 (0%) | 6/23 (26.1%) |
| Event | eCoin Tibial Nerve Stimulation |
|---|---|
| Incision site discomfortGeneral disorders | 3/23 |
| Incision site swellingGeneral disorders | 3/23 |
| Incision site erythemaSkin and subcutaneous tissue disorders | 1/23 |
| DermatitisSkin and subcutaneous tissue disorders | 1/23 |
| Age, Categorical(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 9 |
| >=65 years | 14 |
| Age, Continuous(years) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 63.6 ± 11.0 |
| Sex: Female, Male(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| Female | 22 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | eCoin Tibial Nerve Stimulation |
|---|---|
| New Zealand | 9 |
| United States | 14 |
| Mean UUI Episodes/Day(episodes/day) | eCoin Tibial Nerve Stimulation |
|---|---|
| Mean | 4.8 ± 3.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Jan 2020, 10 months.
Results were first posted in Apr 2021, 1 year 2 months after primary completion.
Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 10 months is below that.
Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valencia Technologies Corporation